Jump to: navigation, search
Iproniazide wiki str.png
Clinical data
AHFS/Drugs.comInternational Drug Names
  •  ?
Routes of
ATC code
Legal status
Legal status
  •  ?
Pharmacokinetic data
Elimination half-life?
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass179.219 g/mol
3D model (JSmol)

WikiDoc Resources for Iproniazide


Most recent articles on Iproniazide

Most cited articles on Iproniazide

Review articles on Iproniazide

Articles on Iproniazide in N Eng J Med, Lancet, BMJ


Powerpoint slides on Iproniazide

Images of Iproniazide

Photos of Iproniazide

Podcasts & MP3s on Iproniazide

Videos on Iproniazide

Evidence Based Medicine

Cochrane Collaboration on Iproniazide

Bandolier on Iproniazide

TRIP on Iproniazide

Clinical Trials

Ongoing Trials on Iproniazide at Clinical Trials.gov

Trial results on Iproniazide

Clinical Trials on Iproniazide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Iproniazide

NICE Guidance on Iproniazide


FDA on Iproniazide

CDC on Iproniazide


Books on Iproniazide


Iproniazide in the news

Be alerted to news on Iproniazide

News trends on Iproniazide


Blogs on Iproniazide


Definitions of Iproniazide

Patient Resources / Community

Patient resources on Iproniazide

Discussion groups on Iproniazide

Patient Handouts on Iproniazide

Directions to Hospitals Treating Iproniazide

Risk calculators and risk factors for Iproniazide

Healthcare Provider Resources

Symptoms of Iproniazide

Causes & Risk Factors for Iproniazide

Diagnostic studies for Iproniazide

Treatment of Iproniazide

Continuing Medical Education (CME)

CME Programs on Iproniazide


Iproniazide en Espanol

Iproniazide en Francais


Iproniazide in the Marketplace

Patents on Iproniazide

Experimental / Informatics

List of terms related to Iproniazide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Iproniazid (Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class.[1][2] It was discontinued in most of the world in the 1960s, but remained in use in France up until fairly recently.[3]

Iproniazid was originally developed for the treatment of tuberculosis,[1] but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy.[1] Subsequently N-isopropyl addition lead to development as an antidepressant and was approved for use in 1958.[1] It was withdrawn a few years later in 1961 due to a high incidence of hepatitis, and was replaced by less hepatotoxic drugs such as phenelzine and isocarboxazid.[1]

Although iproniazid was one of the first antidepressants ever marketed, amphetamine (marketed as Benzedrine from 1935, for "mild depression", amid other indications)[4] predates it; and frankincense has been marketed traditionally for millennia for, among other things, altering mood, although it was not until 2012 that one of the components of its smoke was found to have antidepressant effects in mice.[5] [6] [7]



Condensation of isoniazid with acetone at the basic nitrogen gives the corresponding Schiff base. Catalytic hydrogenation affords the antidepressant iproniazid.


Prepd by treating isoniazid with isopropyl bromide in absolute alcohol in the presence of sodium.

See also


  1. 1.0 1.1 1.2 1.3 1.4 Robert A. Maxwell, Shohreh B. Eckhardt (1990). Drug discovery. Humana Press. pp. 143–154. ISBN 0-89603-180-2. ISBN 9780896031807.
  2. Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical pharmacology. 35 (8): 1381–7. doi:10.1016/0006-2952(86)90285-6. PMID 2870717.
  3. Maille F, Duvoux C, Cherqui D, Radier C, Zafrani ES, Dhumeaux D (October 1999). "[Auxiliary hepatic transplantation in iproniazid-induced subfulminant hepatitis. Should iproniazid still be sold in France?]". Gastroenterol. Clin. Biol. (in French). 23 (10): 1083–5. PMID 10592880.
  4. Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present – a pharmacological and clinical perspective". J. Psychopharmacol. 27 (6): 479–96. doi:10.1177/0269881113482532. PMC 3666194. PMID 23539642.
  5. Moussaieff, Arieh; Rimmerman, Neta; Bregman, Tatiana; Straiker, Alex; Felder, Christian C.; Shoham, Shai; Kashman, Yoel; Huang, Susan M.; Lee, Hyosang; Shohami, Esther; Mackie, Ken; Caterina, Michael J.; Walker, J. Michael; Fride, Ester; Mechoulam, Raphael (August 2008). "Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain". 22 (8). The FASEB Journal: 3024–3034. doi:10.1096/fj.07-101865. PMC 2493463. PMID 18492727.
  6. Moussaieff, A; Gross, M; Nesher, E; Tikhonov, T; Yadid, G; Pinhasov, A (2012). "Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals". J Psychopharmacol. 26 (12). doi:10.1177/0269881112458729. PMID 23015543.
  7. Drahl, Carmen (22 December 2008). "Frankincense And Myrrh". Chemical & Engineering News. 86 (51): 38. doi:10.1021/cen-v086n051.p038. ISSN 0009-2347.
  8. Template:Cite DOI
  9. McMillan et al., J. Am. Pharm. Assoc. Sci. Ed. 42, 457 (1953).
  10. "Simple Accordion with CSS & jQuery by Soh Tanaka". Orgsyn.org. Retrieved 2015-04-12.

Template:Monoaminergics Template:Hydrazines